184 related articles for article (PubMed ID: 7512278)
1. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
[No Abstract] [Full Text] [Related]
2. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.
Akaza H; Kotake T; Miyanaga N; Koiso K
Semin Oncol; 1994 Feb; 21(1 Suppl 1):70-4. PubMed ID: 7512280
[No Abstract] [Full Text] [Related]
3. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
4. The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer.
Saijo N; Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y
Semin Oncol; 1994 Feb; 21(1 Suppl 1):54-8. PubMed ID: 7512277
[No Abstract] [Full Text] [Related]
5. Dose intensity in small cell lung cancer.
Thatcher N; Lee SM; Woll PJ; Middleton M; Anderson H; Burt P; Stout R
Semin Oncol; 1998 Apr; 25(2 Suppl 4):12-8; discussion 45-8. PubMed ID: 9578057
[TBL] [Abstract][Full Text] [Related]
6. Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?
Croockewit AJ; Koopmans PP; de Pauw BE
Clin Pharmacol Ther; 1996 Jan; 59(1):1-6. PubMed ID: 8549028
[No Abstract] [Full Text] [Related]
7. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
[TBL] [Abstract][Full Text] [Related]
8. Combined chemotherapy and irradiation for transitional cell cancer of the bladder: a review.
Beuzeboc P; Pontvert D; Pouillart P; Cosset JM
J Infus Chemother; 1995; 5(4):218-20. PubMed ID: 8934733
[No Abstract] [Full Text] [Related]
9. Preliminary experience with paclitaxel in advanced bladder cancer.
Roth BJ
Semin Oncol; 1995 Jun; 22(3 Suppl 6):1-5. PubMed ID: 7541150
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy dose-escalation with hemopoietic growth factor support in ovarian cancer.
Willemse PH; Boonstra H; de Vries EG
Semin Oncol; 1994 Dec; 21(6 Suppl 16):44-50. PubMed ID: 7528450
[No Abstract] [Full Text] [Related]
11. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
Walther PJ
Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
[No Abstract] [Full Text] [Related]
12. Management of disseminated disease in the patient with bladder cancer.
Perry JJ; Muss HB
Urol Clin North Am; 1994 Nov; 21(4):661-72. PubMed ID: 7974898
[TBL] [Abstract][Full Text] [Related]
13. Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy.
Fisher DC; Peters WP
Curr Opin Hematol; 1994 May; 1(3):221-7. PubMed ID: 9371286
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for non-organ confined bladder transitional cell carcinoma.
Abi-Aad AS
Acta Urol Belg; 1996 May; 64(2):35-7. PubMed ID: 8701808
[No Abstract] [Full Text] [Related]
16. Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.
Gagliano RG; Stephens RL; Costanzi JJ; Oishi N; Stuckey WJ; Grozea PN; Frank J; Crawford ED
Cancer Treat Rep; 1984; 68(7-8):1025-6. PubMed ID: 6430559
[No Abstract] [Full Text] [Related]
17. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
[TBL] [Abstract][Full Text] [Related]
18. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
Pollera CF; Nelli F
Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
[TBL] [Abstract][Full Text] [Related]
19. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group.
Dreicer R; Roth B; Wilding G;
Cancer; 2003 Apr; 97(8 Suppl):2109-14. PubMed ID: 12673703
[TBL] [Abstract][Full Text] [Related]
20. The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Rüther U; Metzner B; Illiger HJ; Clemm C; Siegert W; Link H; Ostermann H; Schmoll HJ
Semin Oncol; 1994 Dec; 21(6 Suppl 16):57-63. PubMed ID: 7801148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
